Q1 FY27 results analysis · August 03, 2026
Glaxosmithkline Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 16.55%, Subsidiary PAT Loss Weighs
+15.7%PAT year on year, Rs. 237.18 Cr
Quick summary
Glaxosmithkline Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 938.44 Cr (+16.55% YoY) and PAT growth of +15.69% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | August 03, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 938.44 Cr (+16.55% YoY) |
| PAT (Q1) | Rs. 237.18 Cr (+15.69% YoY) |
| EBITDA margin | 31.49% (+29 bps YoY) |
| EPS (Q1) | Rs. 14.00 (+15.70% YoY) |
| Market cap | Rs. 45,134.11 Cr |
| CMP | Rs. 2,662.30 |
Quarter Snapshot
GLAXO reported strong 16.55% YoY revenue growth, recovering from supply chain disruptions and outpacing the IPM. Cost management improved material costs despite API price hikes. Concerns include higher other expenses and a subsidiary PAT loss.
Key Investment Insights
Key Positives
- Consolidated revenue grew 16.55% YoY to Rs.938.44 Cr, recovering from supply chain disruption.
- EBITDA margin expanded 29 bps YoY to 31.49% despite API price increases.
- Material cost as % of revenue improved to 34.23% from 35.78% YoY, demonstrating cost management.
- Revenue growth outpaced IPM growth of 10-11%, indicating market share gains.
- PAT grew 15.69% YoY (consolidated) and 23.76% (standalone).
- Supply chain constraints fully resolved, enabling strong growth.
Risk Factors
- Other expenses increased to 16.85% of revenue from 14.11% in Q1 FY26, pressuring margins.
- Subsidiary Biddle Sawyer recorded a PAT loss of Rs.16.15 Cr in Q1 FY27, reversing from a profit of Rs.24.16 Cr in FY26, dragging consolidated PAT.
- Revenue declined 5.71% QoQ, consistent with seasonality but still a sequential decline.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.